(ILMN) Illumina - Ratings and Ratios
Sequencing Instruments, Consumables, Whole Genome Kits, Genotyping Services
ILMN EPS (Earnings per Share)
ILMN Revenue
Description: ILMN Illumina
Illumina Inc (NASDAQ:ILMN) is a leading provider of genetic and genomic analysis solutions, offering a range of sequencing- and array-based instruments and consumables to various customers, including research centers, academic institutions, and pharmaceutical companies. The companys products and services enable the analysis of genetic data, facilitating advancements in fields such as genomics, precision medicine, and consumer genomics.
From a business perspective, Illuminas revenue streams are diversified across various customer segments, including genomic research centers, pharmaceutical and biotechnology companies, and clinical laboratories. The companys direct sales model, supplemented by partnerships with life-science distributors, allows for a strong global presence. Key performance indicators (KPIs) to monitor include revenue growth, gross margin expansion, and the adoption rate of new technologies, such as next-generation sequencing (NGS).
To further evaluate Illuminas performance, its essential to examine metrics such as the number of sequencing instruments sold, the growth of consumables revenue, and the companys research and development (R&D) pipeline. Additionally, monitoring the competitive landscape, including the market share of rival companies, can provide insights into Illuminas market position and potential areas for growth. Other relevant KPIs include the companys operating expenses as a percentage of revenue, return on equity (ROE), and the cash conversion cycle.
Given the companys significant presence in the genomics and life sciences industries, its also crucial to track industry trends, such as the growth of precision medicine, the adoption of NGS in clinical settings, and the development of new genetic testing technologies. By analyzing these factors, investors and analysts can gain a deeper understanding of Illuminas growth prospects and competitive positioning.
ILMN Stock Overview
| Market Cap in USD | 14,620m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2000-07-28 |
ILMN Stock Ratings
| Growth Rating | -74.6% |
| Fundamental | 78.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -36.7% |
| Analyst Rating | 3.68 of 5 |
ILMN Dividends
Currently no dividends paidILMN Growth Ratios
| Growth Correlation 3m | 36.8% |
| Growth Correlation 12m | -63% |
| Growth Correlation 5y | -91.6% |
| CAGR 5y | -21.38% |
| CAGR/Max DD 3y | -0.30 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -1.11 |
| Alpha | -35.86 |
| Beta | 0.485 |
| Volatility | 43.01% |
| Current Volume | 1515.8k |
| Average Volume 20d | 1211.5k |
| Stop Loss | 92.1 (-3.2%) |
| Signal | -1.81 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.26b TTM) > 0 and > 6% of Revenue (6% = 257.0m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 11.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.54% (prev 5.67%; Δ 21.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 1.15b <= Net Income 1.26b (YES >=105%, WARN >=100%) |
| Net Debt (1.58b) to EBITDA (1.78b) ratio: 0.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.81 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (158.0m) change vs 12m ago -0.63% (target <= -2.0% for YES) |
| Gross Margin 66.55% (prev 62.02%; Δ 4.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 70.41% (prev 72.83%; Δ -2.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.57 (EBITDA TTM 1.78b / Interest Expense TTM 111.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.20
| (A) 0.19 = (Total Current Assets 2.64b - Total Current Liabilities 1.46b) / Total Assets 6.09b |
| (B) -0.14 = Retained Earnings (Balance) -876.0m / Total Assets 6.09b |
| (C) 0.25 = EBIT TTM 1.51b / Avg Total Assets 6.08b |
| (D) -0.26 = Book Value of Equity -895.0m / Total Liabilities 3.48b |
| Total Rating: 2.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.06
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 6.51% = 3.26 |
| 3. FCF Margin 24.07% = 6.02 |
| 4. Debt/Equity 0.82 = 2.17 |
| 5. Debt/Ebitda 1.20 = 1.46 |
| 6. ROIC - WACC 20.17% = 12.50 |
| 7. RoE 53.12% = 2.50 |
| 8. Rev. Trend -52.05% = -2.60 |
| 9. Rev. CAGR -1.86% = -0.31 |
| 10. EPS Trend 62.72% = 1.57 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ILMN shares?
Over the past week, the price has changed by -3.85%, over one month by -2.32%, over three months by +7.93% and over the past year by -24.66%.
Is Illumina a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ILMN is around 70.30 USD . This means that ILMN is currently overvalued and has a potential downside of -26.09%.
Is ILMN a buy, sell or hold?
- Strong Buy: 7
- Buy: 5
- Hold: 11
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the ILMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 112 | 17.7% |
| Analysts Target Price | 112 | 17.7% |
| ValueRay Target Price | 77.3 | -18.7% |
Last update: 2025-09-13 04:36
ILMN Fundamental Data Overview
CCE Cash And Equivalents = 934.0m USD (last quarter)
P/E Trailing = 12.0405
P/E Forward = 20.0401
P/S = 3.4127
P/B = 6.7599
P/EG = 0.622
Beta = 1.432
Revenue TTM = 4.28b USD
EBIT TTM = 1.51b USD
EBITDA TTM = 1.78b USD
Long Term Debt = 1.49b USD (from longTermDebt, last quarter)
Short Term Debt = 657.0m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (Calculated: Short Term 657.0m + Long Term 1.49b)
Net Debt = 1.58b USD (from netDebt column, last quarter)
Enterprise Value = 15.83b USD (14.62b + Debt 2.15b - CCE 934.0m)
Interest Coverage Ratio = 13.57 (Ebit TTM 1.51b / Interest Expense TTM 111.0m)
FCF Yield = 6.51% (FCF TTM 1.03b / Enterprise Value 15.83b)
FCF Margin = 24.07% (FCF TTM 1.03b / Revenue TTM 4.28b)
Net Margin = 29.37% (Net Income TTM 1.26b / Revenue TTM 4.28b)
Gross Margin = 66.55% ((Revenue TTM 4.28b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Tobins Q-Ratio = -17.69 (set to none) (Enterprise Value 15.83b / Book Value Of Equity -895.0m)
Interest Expense / Debt = 1.16% (Interest Expense 25.0m / Debt 2.15b)
Taxrate = 23.20% (71.0m / 306.0m)
NOPAT = 1.16b (EBIT 1.51b * (1 - 23.20%))
Current Ratio = 1.81 (Total Current Assets 2.64b / Total Current Liabilities 1.46b)
Debt / Equity = 0.82 (Debt 2.15b / last Quarter total Stockholder Equity 2.61b)
Debt / EBITDA = 1.20 (Net Debt 1.58b / EBITDA 1.78b)
Debt / FCF = 2.08 (Debt 2.15b / FCF TTM 1.03b)
Total Stockholder Equity = 2.37b (last 4 quarters mean)
RoA = 20.67% (Net Income 1.26b, Total Assets 6.09b )
RoE = 53.12% (Net Income TTM 1.26b / Total Stockholder Equity 2.37b)
RoCE = 39.02% (Ebit 1.51b / (Equity 2.37b + L.T.Debt 1.49b))
RoIC = 27.08% (NOPAT 1.16b / Invested Capital 4.27b)
WACC = 6.91% (E(14.62b)/V(16.77b) * Re(7.80%)) + (D(2.15b)/V(16.77b) * Rd(1.16%) * (1-Tc(0.23)))
Shares Correlation 3-Years: 58.03 | Cagr: 0.06%
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈761.0m ; Y1≈499.6m ; Y5≈228.5m
Fair Price DCF = 29.22 (DCF Value 4.49b / Shares Outstanding 153.7m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -52.05 | Revenue CAGR: -1.86%
Rev Growth-of-Growth: -3.34
EPS Correlation: 62.72 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 149.0
Additional Sources for ILMN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle